Eli Lilly is escalating its fight against the black market for unapproved obesity drugs, publicly demanding that credit card companies, payment processors, social media platforms, e-commerce sites, and shipping firms stop servicing vendors selling products marketed as retatrutide.
The pharmaceutical company laid out that demand on August 12 alongside six new lawsuits targeting sellers of these products. A Lilly spokesperson told Axios that federal authorities should pursue the strongest actions available under law, including seizures, injunctions, and criminal prosecutions.
The campaign marks a notable shift in enforcement strategy. Rather than relying solely on litigation against individual sellers, Lilly is pressing the infrastructure that makes black-market sales possible—payment processing, online advertising, and product shipping.
What happened
Lilly’s August 12 announcement combined two enforcement tracks. First, the company filed six new lawsuits against vendors selling products marketed as retatrutide, an obesity drug that has not been approved by regulators. Second, Lilly publicly called on intermediaries—credit card networks, payment processors, social media companies, online marketplaces, and shipping carriers—to stop facilitating those sales.
A Lilly spokesperson told Axios that federal authorities should take the strongest actions the law allows, specifically naming seizures, injunctions, and criminal prosecutions. The company’s push was reported the same week Axios highlighted gaps in federal enforcement against the broader black market for GLP-1 and related obesity drugs.
Why it matters
Lilly’s multi-front pressure campaign signals a more aggressive posture than prior GLP-1 enforcement efforts. By targeting payment processors and distribution infrastructure rather than only individual sellers, the company is attempting to choke off the economic channels that sustain the retatrutide black market.
If processors and platforms comply, the impact could extend well beyond the vendors named in Lilly’s lawsuits. Peptide telehealth platforms, compounding pharmacies, research-use-only peptide sellers, and other merchants operating in adjacent spaces could face tighter restrictions on payment processing and online advertising.
Groups that may face pressure include:
- Peptide telehealth platforms
- Compounding pharmacies
- Research-use-only peptide sellers
- Payment processors and credit card networks
- Social media platforms and online marketplaces
- Consumers seeking unapproved peptides
Axios’s reporting also pointed to a federal enforcement gap: while Lilly can file civil lawsuits and pressure private companies, criminal prosecutions and product seizures require action by federal authorities—a step Lilly is now explicitly urging.
What to watch next
- Whether major payment processors and card networks change policies for peptide-linked merchants
- Whether social media platforms and e-commerce sites pull retatrutide listings in response to Lilly’s demands
- Whether federal agencies act on Lilly’s call for seizures, injunctions, or criminal prosecutions
- Whether the enforcement strategy expands beyond retatrutide to other unapproved or compounded peptides
- How compounding pharmacies and telehealth platforms respond to tightened payment and distribution infrastructure
Sources
Industry information only. Not medical or legal advice.
